From this month, the cost of a 10-minute, six-monthly Ocrevus (ocrelizumab) subcutaneous injection for relapsing-remitting multiple sclerosis (MS) will be slashed from more than $16,500 to $31.60 for ...

Thousands of Australians battling a debilitating form of multiple sclerosis have been granted a reprieve, as a groundbreaking injection treatment is added to Australia’s Pharmaceutical Benefits Scheme ...

Finally, a family friend who worked as a healthcare provider in urgent care took her concerns seriously, ordered tests, and asked if she’d ever had an MRI. Within a month, Chelsea had her first scan ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.